Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 6/20 | 0.68 |
| ▸ | NMBR | P28336 | 2/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.61 |
| ▸ | ITGAV | P06756 | 2/20 | 0.61 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.59 |
| ▸ | CTSH | P09668 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | GLP1R | P43220 | 3/20 | 0.58 |
| ▸ | GCGR | P47871 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bombesin SCHEMBL29364598 | 0.97 | GRPR (0.66) | GRPRNMBRITGB3ITGAVCTSL | |
| SCHEMBL31738529 | 0.94 | GRPR (0.62) | GRPRNMBRITGB3ITGAVCTSL | |
| SCHEMBL30783571 | 0.91 | GRPR (0.65) | GRPRNMBR | |
| Bombesin SCHEMBL29353003 | 0.90 | GRPR (0.70) | GRPRNMBR | |
| Bombesin SCHEMBL29711302 | 0.90 | GRPR (0.76) | GRPR | |
| Bombesin SCHEMBL3049338 | 0.90 | GRPR (0.76) | GRPR | |
| SCHEMBL30312760 | 0.89 | GRPR (0.69) | GRPRNMBRITGB3ITGAVCTSL | |
| SCHEMBL30192248 | 0.88 | GRPR (0.71) | GRPRNMBRCTSLCTSSCTSK | |
| SCHEMBL31694516 | 0.87 | GLP1R (0.63) | IL23RGLP1RGCGR | |
| SCHEMBL19365036 | 0.86 | GRPR (0.57) | GRPRNMBRITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548096-B1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11660354-B2 | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3256466-B9 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3256466-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660354-B2 | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof | GRPR, GIPR, PSMA1 | GRPR 1/4885NMBR 176/4885ITGB3 1661/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | GRPR 645/4885NMBR 617/4885ITGB3 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.